Written by Charles Gumbley, BHSc (Clinical Nutrition), DipHSc (Western Herbal Medicine)
Evidence checked: 19 July 2026
A mushroom supplement must not replace cancer treatment, infection care, diabetes treatment or assessment of neurological symptoms. Talk with the treating clinician before use alongside chemotherapy, immunotherapy, transplantation medicines, anticoagulants or glucose-lowering medicines.
Conflict disclosure: Nutrition Market sells supplements. This article contains no products, categories, prices, stock feeds or shop links.
Medicinal mushrooms benefits are often described as though every mushroom, powder and extract produces the same outcome. That is not how the evidence works. Reishi, turkey tail, lion’s mane, chaga, cordyceps and maitake are different fungi. A whole edible mushroom, fruiting-body powder, cultured mycelium, hot-water extract and isolated compound are not interchangeable interventions.
The most useful question is not which fungus has the longest benefits list. It is whether a defined mushroom product has credible human evidence for a specific outcome, whether that exact preparation is legal and appropriately regulated in Australia, and whether its risks fit the person considering it.
Key points
- Most broad proposed benefits begin with laboratory, animal or biomarker findings rather than confirmed patient outcomes.
- A clinical trial of one named extract cannot prove that every product from the same species works.
- Products making therapeutic claims in Australia may need ARTG inclusion and compliant advertising.
- “Immune support” does not mean preventing infection, treating cancer or improving immunity in every person.
- Chaga has an oxalate-related kidney-injury signal; reishi and other mushrooms can also create interaction concerns.
What is a medicinal mushroom?
“Medicinal mushroom” is a commercial and traditional-use description, not one standard pharmacological category. The fungi grouped under it include different species, chemical profiles and preparations. Some are edible mushrooms used as foods. Others are woody fungi traditionally prepared as decoctions or concentrated mushroom extracts rather than eaten as a meal.
Mushroom cell walls contain polysaccharides, including beta-glucans. Species may also contain triterpenes, sterols, phenolic compounds and proteins. These bioactive compounds can influence cells or signalling pathways in laboratory models. That establishes biological interest, not a clinical benefit. Digestion, dose, extraction, contamination, metabolism and the studied population all sit between a laboratory mechanism and a health outcome.
Names can also conceal identity problems. Reishi may refer to several Ganoderma species, while products sold under common names may not contain the purified polysaccharide preparations studied overseas. A label that says mushroom blend without scientific names, plant part, extraction method and ingredient amounts gives readers little basis for comparing it with research.
Types of medicinal mushrooms and potential benefits
Scroll sideways to read the full table →
| Mushroom | What human research can reasonably say | What it cannot establish |
|---|---|---|
| Reishi mushroom (Ganoderma species) | Clinical trials have measured metabolic, immune and quality-of-life outcomes, with mixed or null results across many endpoints. | Effectiveness against cancer, clinically meaningful glucose or cholesterol reduction, or stronger immunity from retail reishi. |
| Turkey tail mushroom (Trametes versicolor) | Specific purified polysaccharide products have been studied as adjuncts to standard cancer care in some countries. | Equivalence of an Australian powder or tincture, or standalone efficacy against cancer. |
| Lion’s mane (Hericium erinaceus) | Several small clinical trials and pilots have explored cognition and mood; evidence remains preliminary and preparation-specific. | Prevention or treatment of dementia, depression, anxiety or neurological disease. |
| Chaga (Inonotus obliquus) | Laboratory research describes compounds and antioxidant activity; meaningful human benefit evidence is inadequate. | Cancer treatment, immune protection, glucose control or a safe universal daily dose. |
| Cordyceps species | Small studies use varying cultured fungi and extracts for exercise or fatigue-related outcomes. | A class effect across wild, cultivated and blended products or treatment of chronic fatigue. |
| Maitake and shiitake | Edible mushrooms contribute nutrients as foods; specific extracts and compounds remain separate research interventions. | That eating the food reproduces the effect of an isolated compound or therapeutic extract. |
This table deliberately separates research possibilities from treatment claims. A mushroom may contain an interesting compound without proving that consuming the finished preparation changes health, symptoms or disease risk.
Edible mushroom, mushroom powder and mushroom extract
Food and therapeutic preparations answer different questions. White button mushroom, oyster mushroom and shiitake mushrooms are common foods. Button mushrooms can contribute fibre, protein and micronutrients as part of an ordinary diet. That food role does not establish the effects of mushrooms sold as concentrated extracts, nor does an extract study prove that a serving of food produces the same exposure.
A powder may contain milled fruiting body, cultured mycelium, residual grain substrate or a mixture. A mushroom extract adds another variable: water, alcohol or both may concentrate different constituents. The stated extract ratio describes manufacturing input and output; it is not a direct measure of absorption, clinical potency or outcome. Two products carrying the same species name can therefore be materially different. The mushroom also needs verified identity before any research comparison is credible.
Wild mushrooms add identification and contamination risks. Do not forage on the strength of an online photograph, and do not assume that “natural” means edible. Poisonous species can resemble culinary types of mushrooms. In Australia, contact the Poisons Information Centre on 13 11 26 for suspected ingestion; call 000 for collapse, breathing difficulty, severe symptoms or altered consciousness.
Some literature describes mushrooms as both nutritional and medicinal. That phrase should not blur the boundary between food composition and therapeutic evidence. The properties of mushrooms in a laboratory, their nutrient contribution as foods and the effects of a defined clinical intervention are three separate questions.
Reishi mushroom evidence from clinical trials
A 2025 GRADE-assessed systematic review and meta-analysis pooled 17 randomised trials involving 971 participants.¹ The reishi preparations, populations and durations varied. The analysis reported small changes in some measures, but no significant effects on blood pressure, fasting glucose, lipid profile, inflammatory markers or liver enzymes.
That pattern matters because marketing often selects a positive biomarker while ignoring null outcomes and study heterogeneity. A small average change is not automatically clinically meaningful, and it does not identify a preferred reishi preparation. The review does not support cardiovascular prevention or diabetes management claims.
Cancer evidence needs an even firmer boundary. The National Cancer Institute describes studies of specific preparations, including purified turkey-tail polysaccharides used as adjunctive treatment in Japan.² It also notes limitations in the evidence and substantial differences between products. A purified agent used with oncology care is not equivalent to a retail powder or extract.
The older Cochrane review of reishi for cancer found insufficient evidence to justify it as a first-line treatment, and the included trials did not establish long-term survival. Cancer treatment decisions must remain with the oncology team. Public-facing Australian therapeutic-goods advertising also cannot freely make cancer claims.
Lion’s mane mushroom and cognitive health claims
Lion’s mane is promoted for memory, focus, nerve growth and brain health. A 2025 systematic review included five randomised controlled trials, three pilot clinical trials and a much larger body of laboratory work.³ Some small human studies reported changes in cognitive or mood measures, but populations, products and outcomes differed.
The review also included cell and animal findings. Those results should not be merged with human clinical evidence. A compound affecting nerve-growth pathways in a laboratory does not show that a lion’s mane mushroom prevents dementia or repairs nerves in people.
Anyone with new memory loss, personality change, weakness, altered sensation, severe headache or functional decline needs medical assessment. Self-treatment should never postpone investigation. Mushroom allergy and gastrointestinal adverse effects also remain possible.
Turkey tail, the immune system and cancer language
Beta-glucans and other polysaccharides can interact with immune pathways, which is why researchers measure cytokines, natural killer cells and other markers. A change in an immune marker is not the same as fewer infections, better cancer survival or an “optimised” immune system.
The immune system is not a single dial that should always be turned upwards. Autoimmune disease, transplantation and cancer immunotherapy involve complex and sometimes opposing clinical goals. A fungal extract that affects an immune pathway could be inappropriate in a particular treatment plan even if the label sounds supportive.
Turkey-tail evidence illustrates the product problem. PSK and PSP are defined preparations, not synonyms for every turkey-tail powder. Species confirmation, strain, substrate, extraction and standardisation matter. Do not transfer an overseas adjunctive-treatment study to an unrelated Australian product.
Chaga mushroom and kidney safety
Chaga is a fungus that grows mainly on birch trees and is sold as chunks, tea, powder and extract. Claims about antioxidant compounds or laboratory anticancer effects do not establish a human benefit. The more actionable evidence is a safety signal involving oxalate.
Published case reports describe oxalate crystal deposition and kidney injury after sustained, high chaga intake.⁴ A 2026 rat study using exposure levels modelled from a reported clinical case found oxalate deposition, tubular injury and other kidney changes at high intake.⁵ Animal evidence cannot calculate the risk from ordinary use, but it supports caution rather than a blanket safety claim.
People with kidney disease, kidney stones, high oxalate risk or relevant dietary restrictions should not self-prescribe chaga. Combining concentrated chaga with high-dose vitamin C may add to oxalate exposure. Sudden reduction in urine, swelling, severe nausea, flank pain or unexplained fatigue warrants medical care, not another self-treatment.
Australian regulation of mushroom products
The Therapeutic Goods Administration distinguishes foods from therapeutic goods by ingredients, presentation, processing and claims.⁶ Whole or dried mushrooms traditionally consumed as food may be regulated as foods. Capsules, tinctures, concentrated extracts and products presented for therapeutic use are likely to be therapeutic goods.
Therapeutic mushroom products generally need inclusion in the Australian Register of Therapeutic Goods before advertising or supply. Check the label for an AUST number and verify the ARTG entry. An AUST L listing does not mean the regulator has individually confirmed that the product delivers every claimed benefit before sale.
Claims must also match the product’s permitted indications and evidence. Cancer, serious cardiovascular disease and other restricted or prohibited representations cannot be used casually. The current live article’s old claims about cancer treatment, glucose regulation, cholesterol reduction and immune stimulation are therefore removed rather than softened.
Best medicinal mushroom supplements: how to assess a product
This comparison search phrase is not an evidence-based universal ranking. Before considering a dietary supplement, write down the purpose and the outcome that would show a meaningful change. Then check:
- Species: Look for a scientific name, not only reishi, chaga or a proprietary blend.
- Material: Identify fruiting body, mycelium, spores or a combination. Grain-grown mycelium can include substantial substrate.
- Extraction: Note whether it is whole powder, hot-water extract, alcohol extract or dual extract. Do not assume extraction ratios equal clinical potency.
- Standardisation: A beta-glucan or triterpene number is a quality detail, not proof of a health outcome.
- Regulatory status: Check the AUST number and ARTG record when the product is presented for therapeutic use.
- Testing: Look for credible identity, microbial, heavy-metal and contaminant testing tied to the batch.
- Interaction review: Check medicines, planned surgery, pregnancy, breastfeeding, allergy, kidney and liver history with a pharmacist or treating practitioner.
- Review point: Trial one change at a time and stop if there is no defined benefit or an adverse effect appears.
“Best” cannot be decided from the highest extract ratio, most species in a blend or largest beta-glucan number. The best evidence match, if one exists, is the exact preparation studied for the exact outcome in a comparable population.
Medicinal mushroom clinical trial checklist
When a label or article cites a clinical trial, check the PICO details: the participants, intervention, comparator and outcome. A useful result in adults with one diagnosed condition may not apply to healthy adults, children or people taking several medicines. The dose, mushroom species, extraction method, product standardisation and treatment duration should match before drawing a comparison.
Then inspect the outcome. A symptom scale or patient-important outcome usually says more than a single laboratory marker. Claims that mushrooms may help improve insulin resistance, for example, require consistent human evidence on validated metabolic outcomes, not merely an experiment in cells or rodents. The 2025 reishi review did not establish that result.
Study design matters too. Small, unblinded trials, numerous outcomes and short follow-up increase uncertainty. A systematic review can still be limited when its component trials study different preparations. “Statistically significant” does not tell readers whether the average difference was large enough to matter in daily life.
Finally, inspect funding, registration, selective reporting and harms. A paper about selected fungal species may discuss their research potential while offering no evidence that an available Australian product has the same composition. Absence of reported harm in a small study is not proof of long-term safety. “Medical mushroom” is not a shortcut around this product-level assessment, and a supplement cannot be presumed equivalent to the studied intervention.
Reishi health benefits: language versus evidence
Search results use overlapping language about reishi benefits, including health benefits of reishi mushrooms. Repetition does not strengthen the evidence. Polysaccharides in reishi mushrooms and other constituents have plausible biological activity, but a mechanism cannot establish a treatment effect.
Reishi has been used in traditional Chinese medicine, and medicinal mushrooms have been used in several food and healing traditions. Historical use can guide research questions; it does not replace modern product identification, dose information, controlled comparison or adverse-event monitoring. Claims about the oldest fungi used this way are therefore historical claims, not rankings of effectiveness. The use of medicinal mushrooms today still requires current evidence and a product-specific safety check.
The same rule applies to maitake mushroom, turkey-tail preparations and the medicinal mushroom Agaricus. A phrase such as “benefits of Agaricus” must be tested against the exact species, preparation and outcome. Do not transfer findings among fungi simply because the compounds found in mushrooms share broad chemical labels.
Mushroom supplement side effects and medicine interactions
Reported adverse effects vary by mushroom and preparation and can include gastrointestinal upset, rash, allergy, headache and dry mouth. Concentrated extracts create different exposures from ordinary edible mushrooms. Contamination or incorrect species identification adds another risk.
Reishi may raise concerns with anticoagulant or antiplatelet medicines and before surgery. Products promoted for glucose or blood pressure can complicate monitoring when used with prescribed medicines. Immune-active claims require particular caution with immunosuppressants, autoimmune conditions, transplantation and oncology treatment.
Pregnancy and breastfeeding safety data are inadequate for many concentrated preparations. Children should not be treated as small adults. If a product causes breathing difficulty, facial swelling, fainting, severe vomiting, jaundice, dark urine or reduced urine output, stop it and seek urgent advice.
Mushroom questions
What are the most beneficial medicinal mushrooms?
There is no universal ranking. Reishi has the broadest clinical-trial literature in this group, while specific turkey-tail preparations have oncology-adjunct research and lion’s mane has small cognition studies. None of that proves a general-purpose winner or transfers to every retail product.
What are the side effects of taking medicinal mushrooms?
Effects depend on the species and preparation. Gastrointestinal symptoms, allergy and medicine interactions are possible. Chaga has an oxalate-related kidney warning, and concentrated products require more caution than culinary use.
What is the best way to consume medicinal mushrooms?
There is no single best method. Culinary mushrooms are foods; powders and extracts are different interventions. Choose only after identifying the exact species, purpose, evidence, regulatory status and interaction profile. This article does not provide a public dose.
Are medicinal mushrooms good for you?
Edible mushrooms can be part of a varied diet. A medicinal fungus preparation should be judged as a specific intervention with a defined purpose, not assumed to be beneficial because mushrooms offer chemically interesting constituents.
References
- Jafari A, et al. Ganoderma lucidum and human health: GRADE-assessed systematic review and meta-analysis. Food Science & Nutrition. 2025. doi:10.1002/fsn3.70423. PubMed
- National Cancer Institute. Medicinal Mushrooms (PDQ), health professional version. NCI
- Menon A, et al. Hericium erinaceus as a supplement: systematic review. 2025. doi:10.3389/fnut.2025.1641246. PubMed
- Kwon O, et al. Chaga mushroom-induced oxalate nephropathy. Medicine. 2022. doi:10.1097/MD.0000000000028997. PubMed
- Lee WC, et al. Kidney injury induced by high-dose chaga mushroom consumption. Journal of Korean Medical Science. 2026. doi:10.3346/jkms.2026.41.e37. PubMed
- Therapeutic Goods Administration. Advertising mushroom products that are therapeutic goods. TGA
- Jin X, et al. Ganoderma lucidum for cancer treatment. Cochrane review. 2016. doi:10.1002/14651858.CD007731.pub3. PubMed
